Article
Oncology
Henan Zhang, Jacob J. Orme, Feven Abraha, B. J. Stish, Val J. Lowe, Fabrice Lucien, Erik J. Tryggestad, Michael S. Bold, Lance C. Pagliaro, C. Richard Choo, Debra H. Brinkmann, Matthew J. Iott, Brian J. Davis, J. Fernando Quevedo, William S. Harmsen, Brian A. Costello, Geoffrey B. Johnson, Mark A. Nathan, Kenneth R. Olivier, Thomas M. Pisansky, Eugene D. Kwon, Haidong Dong, Sean S. Park
Summary: The study showed that high levels of tumor-reactive T cells and effector memory T cells were associated with better outcomes in oligometastatic CRPC patients treated with SABR. This supports the incorporation of immune-based markers in the design of future randomized trials in this patient population.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Lauren T. Maloney, Emile Latour, Yiyi Chen, Douglas Rice, Alison Grossblatt-Wait, Nima Nabavizadeh, Charles R. Thomas, Kristina H. Young, Joshua M. Walker, John Holland, Aaron J. Grossberg
Summary: This study investigates whether patients taking angiotensin receptor blockers (ARBs) during stereotactic body radiotherapy (SBRT) for early stage lung cancer experience improved overall survival (OS) or recurrence-free survival (RFS). The results show that patients taking ARBs during SBRT exhibited increased OS and RFS compared to patients not taking ARBs. However, the use of angiotensin converting enzyme inhibitors (ACEIs) or statins did not show the same effect.
CANCER BIOLOGY & THERAPY
(2022)
Article
Oncology
Nikhil T. Sebastian, Amy Webb, Konstantin Shilo, Ryan Robb, Meng Xu-Welliver, Karl Haglund, Jeremy Brownstein, Gina M. DeNicola, Changxian Shen, Terence M. Williams
Summary: This study validates the association between higher PI3K activity and local recurrence and worse disease-free survival in early-stage NSCLC patients treated with SBRT.
Article
Oncology
Gregory M. M. Videtic, Chandana A. Reddy, Neil M. Woody, Kevin L. Stephans
Summary: The review of ten years of using single-fraction lung stereotactic body radiation therapy for medically inoperable early-stage lung cancer found high survival rates and low toxicity reactions, with no significant differences in outcomes between different dosage levels.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Animesh Saha, Matthew Beasley, Nathaniel Hatton, Peter Dickinson, Kevin Franks, Katy Clarke, Pooja Jain, Mark Teo, Patrick Murray, John Lilley
Summary: In patients treated with SABR for early-stage lung cancer, factors such as tumor location, size, PTV, mean lung dose, etc., need to be considered to predict symptomatic radiation pneumonitis.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Eleni Gkika, Elke Firat, Sonja Adebahr, Erika Graf, Ilinca Popp, Gianluca Radicioni, Simon S. Lo, Ursula Nestle, Nils H. Nicolay, Gabriele Niedermann, Dan G. Duda, Anca-L. Grosu
Summary: We conducted a prospective study to investigate the changes in circulating immune cells after stereotactic body radiotherapy (SBRT) in early-stage NSCLC patients. We found no significant increase in CD8(+) cytotoxic T lymphocytes at the first follow-up, but observed a significant expansion in Ki-67(+)CD8(+) and Ki-67(+)CD4(+) T-cell fractions in patients receiving 10 Gy or less per fraction. Our findings suggest that SBRT can induce immediate expansion of circulating effector T-cells.
NPJ PRECISION ONCOLOGY
(2023)
Article
Oncology
Mihailo Miljanic, Chika Nwachukwu, Assal Rahimi
Summary: This case series and literature review suggest that definitive ablative radiation therapy may serve as a safe and effective treatment option for non-operable patients with early stage breast cancer. The observed durable treatment responses and minimal toxicity support the potential of this approach.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Mihailo Miljanic, Chika Nwachukwu, Assal Rahimi
Summary: This case series and literature review investigate the efficacy and safety of definitive ablative radiation therapy for non-operable patients with early stage breast cancer. The two cases presented demonstrate the potential of this approach to achieve durable responses.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Biology
Kuifei Chen, Liqiao Hou, Meng Chen, Shuling Li, Yangyang Shi, William Y. Raynor, Haihua Yang
Summary: The purpose of this study was to develop a radiogenomic model using F-18-FDG PET/CT radiomics and clinical-parameter EGFR to predict PFS stratification in lung cancer patients after SBRT treatment. The results showed that the radiogenomic model had good accuracy and clinical value in predicting PFS stratification.
Article
Radiology, Nuclear Medicine & Medical Imaging
Francois Lucia, Thomas Louis, Francois Cousin, Vincent Bourbonne, Dimitris Visvikis, Carole Mievis, Nicolas Jansen, Bernard Duysinx, Romain Le Pennec, Malik Nebbache, Martin Rehn, Mohamed Hamya, Margaux Geier, Pierre-Yves Salaun, Ulrike Schick, Mathieu Hatt, Philippe Coucke, Roland Hustinx, Pierre Lovinfosse
Summary: The purpose of this study was to develop machine learning models to predict regional and/or distant recurrence in patients with early-stage non-small cell lung cancer (ES-NSCLC) after stereotactic body radiation therapy (SBRT) using [F-18]FDG PET/CT and CT radiomics combined with clinical and dosimetric parameters.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Oncology
Darren M. C. Poon, Daisy Lam, Kenneth C. W. Wong, Cheuk-Man Chu, Michael Cheung, Frankie Mo, Joyce Suen, Chi-Fai Ng, Anthony T. C. Chan
Summary: This study compared the effects of stereotactic body radiotherapy (SBRT) and conventional fractionated radiotherapy (CFRT) in Chinese men with localized prostate cancer (PC). The results showed that SBRT had similar patient-reported quality of life (PRQOL) but fewer toxicities compared to CFRT in the first year.
Article
Oncology
X. Melody Qu, Yujie Chen, Gregory S. Zaric, Suresh Senan, Robert A. Olson, Stephen Harrow, Ava John-Baptiste, Stewart Gaede, Liam A. Mulroy, Devin Schellenberg, Sashendra Senthi, Anand Swaminath, Neil Kopek, Mitchell Liu, Andrew Warner, George B. Rodrigues, David A. Palma, Alexander Louie
Summary: The study found that SABR treatment has a cost of $37,157 per QALY gained, and is sensitive to the number of metastatic lesions, difference in chemotherapy use, and PFS hazard ratio. Probabilistic sensitivity analysis revealed that SABR was cost-effective in 97% of iterations, while two-way sensitivity analysis demonstrated a nonlinear relationship between the number of lesions and the PFS hazard ratio.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Critical Care Medicine
Yusef A. Syed, William Stokes, Manali Rupji, Yuan Liu, Onkar Khullar, Nikhil Sebastian, Kristin Higgins, Jeffrey D. Bradley, Walter J. Curran, Suresh Ramalingam, James Taylor, Manu Sancheti, Felix Fernandez, Drew Moghanaki
Summary: Facilities with higher use of SBRT for surgery in patients with early stage NSCLC showed lower rates of postoperative mortality. These findings suggest that the availability and use of SBRT may improve the selection of patients predicted to be at high risk of postoperative mortality.
Article
Oncology
Bong Kyung Bae, Kyungmi Yang, Jae Myung Noh, Hongryull Pyo, Yong Chan Ahn
Summary: This study reports the clinical outcomes of proton and photon stereotactic body radiation therapy (SBRT) for early-stage lung cancer. The findings suggest that proton SBRT may be considered for patients at high risk of developing radiation pneumonitis, as it showed comparable oncologic outcomes and toxicity profiles to photon SBRT.
Article
Oncology
Robert Olson, Will Jiang, Mitchell Liu, Alanah Bergman, Devin Schellenberg, Benjamin Mou, Abraham Alexander, Hannah Carolan, Fred Hsu, Stacy Miller, Siavash Atrchian, Elisa Chan, Clement Ho, Islam Mohamed, Angela Lin, Tanya Berrang, Andrew Bang, Nick Chng, Quinn Matthews, Sarah Baker, Vicky Huang, Ante Mestrovic, Derek Hyde, Chad Lund, Howard Pai, Boris Valev, Shilo Lefresene, Scott Tyldesley
Summary: This study confirms that the incidence of high-grade toxic effects in the large cohort of patients receiving SABR for oligometastases is less than 5%. The lower rates of toxic effects compared to previous studies may support further enrollment in randomized phase 3 clinical trials.
Article
Clinical Neurology
Seth A. Climans, Ronald C. Ramos, Paola A. Jablonska, David B. Shultz, Warren P. Mason
Summary: This study retrospectively analyzed the use of bevacizumab for cerebral radionecrosis. The results showed that the clinical benefits of bevacizumab were modest and there were significant toxicities associated with its use.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
(2023)
Article
Oncology
Maura L. Gillison, Robert L. Ferris, Jonathan Harris, A. Dimitrios Colevas, Loren K. Mell, Christina Kong, Richard C. Jordan, Kevin L. Moore, Minh-Tam Truong, Claudia Kirsch, Arnab Chakravarti, Dukagjin M. Blakaj, David A. Clump, James P. Ohr, John F. Deeken, Michael F. Gensheimer, Nabil F. Saba, Jennifer A. Dorth, David I. Rosenthal, Rom S. Leidner, Randall J. Kimple, Mitchell Machtay, Walter J. Curran, Pedro Torres-Saavedra, Quynh Thu Le
Summary: A study found that the concurrent administration of nivolumab with (chemo)radiation is safe and effective for newly diagnosed patients with intermediate and high-risk head and neck squamous cell carcinoma (HNSCC).
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Clinical Neurology
Angela Sekely, Lori J. Bernstein, Kristin L. Campbell, Warren P. Mason, Normand Laperriere, Navya Kalidindi, Rosemarylin Or, Ronald Ramos, Seth A. Climans, Gregory R. Pond, Barbara Ann Millar, David Shultz, Derek S. Tsang, Gelareh Zadeh, Kim Edelstein
Summary: This study found that individuals with glioblastoma (GBM) are at risk of neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms shortly after diagnosis. Depressive symptoms were significantly associated with neurocognitive impairment, highlighting the importance of early identification and treatment of depression in GBM patients.
NEURO-ONCOLOGY PRACTICE
(2023)
Article
Oncology
Li Guan, Dhanya K. Nambiar, Hongbin Cao, Vignesh Viswanathan, Shirley Kwok, Angela B. Hui, Yuan Hou, Rachel Hildebrand, Rie von Eyben, Brittany J. Holmes, Junfei Zhao, Christina S. Kong, Nathan Wamsley, Weiruo Zhang, Michael B. Major, Seung W. Seol, John B. Sunwoo, D. Neil Hayes, Maximilian Diehn, Quynh-Thu Le
Summary: Radiotherapy is a primary treatment for head and neck squamous cell carcinoma (HNSCC), but there is currently no reliable biomarker for predicting radioresistance. This study found that mutations in the NFE2L2 gene are associated with higher rates of locoregional failure in HNSCC patients treated with surgery and (chemo)radiotherapy. NFE2L2 mutations lead to radioresistance through Nrf2 activation, but this can be overcome by the glutaminase inhibitor CB-839.
Article
Oncology
Jimmy J. Caudell, Pedro A. Torres-Saavedra, David I. Rosenthal, Rita S. Axelrod, Phuc Felix Nguyen-Tan, Eric J. Sherman, Randal S. Weber, James M. Galvin, Adel K. El-Naggar, Andre A. Konski, Michelle I. Echevarria, Neal E. Dunlap, George Shenouda, Anurag K. Singh, Jonathan J. Beitler, Adam Garsa, James A. Bonner, Adam S. Garden, Ozer Algan, Jonathan Harris, Quynh-Thu Le
Summary: NRG Oncology conducted a phase 3 trial to test the impact of combining cisplatin and radiation or cetuximab and radiation on the overall survival of patients with locally advanced head and neck carcinoma. After a follow-up of over 10 years, the addition of cetuximab did not improve patient outcomes, regardless of p16 status.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Editorial Material
Oncology
Claire C. Baniel, Daniella Klebaner, Beth M. Beadle, Sara E. Beltran Ponce, Vinita Takiar, Iris C. Gibbs, Scott G. Soltys, Hilary P. Bagshaw, Daniel T. Chang, Quynh-Thu Le, Erqi L. Pollom
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
W. K. Jacky Lam, Ann D. King, Jacob A. Miller, Zhiwei Liu, Kelly J. Yu, Melvin L. K. Chua, Brigette B. Y. Ma, Ming Yuan Chen, Benjamin A. Pinsky, Pei-Jen Lou, John K. S. Woo, Wan-Lun Hsu, Julia Simon, Denise L. Doolan, Tim Waterboer, Edwin P. Hui, Hui Li, Raymond K. Tsang, Kenneth C. W. Wong, Julian P. Goh, Alexander C. Vlantis, Qi Yong Ai, Lun M. Wong, Victor Abdullah, Jin Ching Lin, Chien-Jen Chen, Ruth M. Pfeiffer, Quynh-Thu Le, Anne W. M. Lee, Mingfang Ji, Sumei Cao, Jun Ma, Anthony T. C. Chan, K. C. Allen Chan, Allan Hildesheim
Summary: A meeting of experts in November 2021 discussed the performance and cost-effectiveness of EBV-based approaches for screening early stage nasopharyngeal carcinoma. Both serum EBV antibody and plasma EBV DNA testing methods were found to be favorable. Additionally, the use of MRI was recommended to increase the sensitivity of NPC detection without greatly impacting the cost-effectiveness of the screening program.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Article
Oncology
Eric J. Sherman, Jonathan Harris, Keith C. Bible, Ping Xia, Ronald A. Ghossein, Christine H. Chung, Nadeem Riaz, G. Brandon Gunn, Robert L. Foote, Sue S. Yom, Stuart J. Wong, Shlomo A. Koyfman, Michael F. Dzeda, David A. Clump, Saad A. Khan, Manisha H. Shah, Kevin Redmond, Pedro A. Torres-Saavedra, Quynh-Thu Le, Nancy Y. Lee
Summary: This study is the largest randomized anaplastic thyroid cancer study that has been completed, showing the feasibility and safety of the treatment combination. Although no significant improvement in overall survival was observed in the pazopanib group, hypothesis-generating data were generated that may warrant further investigation.
Article
Multidisciplinary Sciences
Michelle Jun, Harlan Pinto, Quynh-Thu Le, Andrew Quon, Wendy Hara, Jessie Coty, Alex McMillan, Rong Lu, Elzbieta Winters, Ruth Lira, A. Dimitrios Colevas
Summary: This study aimed to evaluate the efficacy and feasibility of full dose docetaxel, platinum, and 5-fluorouracil (TPF) in locally advanced or oligometastatic NPC patients. The results showed that the use of standard dose TPF combined with chemoradiation is both feasible and effective in this patient population.
Editorial Material
Oncology
Brigette B. Y. Ma, Quynh Thu Le
Summary: In this study, the authors present the results of a phase III clinical trial, showing the survival benefit of combining PD-1 inhibitors and chemotherapy in nasopharyngeal cancer. They also identify hot and cold tumor signatures through gene expression analysis, which have prognostic and predictive significance.
Article
Oncology
Adam S. Garden, Jonathan Harris, Avraham Eisbruch, K. S. Clifford Chao, William H. Morrison, Paul M. Harari, Todd Allen Swanson, Christopher U. Jones, Sue S. Yom, Sharon A. Spencer, Rufus Scrimger, George Shenouda, Monica Shukla, Harold Y. Lau, Michelle Mierzwa, Pedro Torres-Saavedra, Quynh Thu Le
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Dhanya K. Nambiar, Vignesh Viswanathan, Hongbin Cao, Weiruo Zhang, Li Guan, Manish Chamoli, Brittany Holmes, Christina Kong, Rachel Hildebrand, Amanda Jeanette Koong, Rie von Eyben, Sylvia Plevritis, Lingyin Li, Amato Giaccia, Edgar Engleman, Quynh Thu Le
Summary: Galectin-1 increases STING stability in cancer cells that activates NF-kappa B signaling and CXCL2 expression to promote MDSC trafficking, which stimulates the generation of a premetastatic niche and facilitates metastatic progression.
Article
Computer Science, Artificial Intelligence
Yizheng Chen, Lequan Yu, Jen-Yeu Wang, Neil Panjwani, Jean-Pierre Obeid, Wu Liu, Lianli Liu, Nataliya Kovalchuk, Michael Francis Gensheimer, Lucas Kas Vitzthum, Beth M. Beadle, Daniel T. Chang, Quynh-Thu Le, Bin Han, Lei Xing
Summary: Defining the loss function is crucial for the success of deep learning modeling. Traditional loss functions treat all regions in the input image equally, but in reality, different regions have different prediction performance. To address this, we introduce a region-specific loss that assigns higher weightings to more difficult sub-regions for better learning.
IEEE TRANSACTIONS ON PATTERN ANALYSIS AND MACHINE INTELLIGENCE
(2023)
Article
Oncology
Elaine Limkin, Pierre Blanchard, Benjamin Lacas, Jean Bourhis, Mahesh Parmar, Lisa Licitra, Quynh-Thu Le, Sue S. Yom, Catherine Fortpied, Johannes Langendijk, Jan B. Vermorken, Jacques Bernier, Jens Overgaard, Jonathan Harris, Jean-Pierre Pignon, Anne Auperin
Summary: This study investigated the impact of season of radiotherapy on the outcomes of head and neck squamous cell cancer patients. The results showed that the season of radiotherapy did not have any significant effect on patient outcomes.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Mauricio Fernando Ribeiro, Hagit Peretz Soroka, Zainab Bhura, Ian Hirsch, Jay Wunder, Peter Ferguson, Kim Tsoi, Savtaj Brar, Rebecca Gladdy, Carol Swallow, Peter Chung, Charles Catton, Philip Wong, Geoffrey Watson, Albiruni Ryan Abdul Razak, Abha A. Gupta, David Shultz
Summary: This study investigates prognostic factors and outcomes for radiation-induced sarcomas (RIS) using the Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) database. The results suggest that surgery is the standard treatment and neoadjuvant chemotherapy (NACT) may be useful for downsizing large lesions in breast angiosarcoma (BAS) patients. The study highlights the importance of accurate diagnosis and appropriate management for RIS.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)